Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

Time to stability

Time in days from randomization until stability defined by temperature \< 38, heart rate \< 100, respiratory rate \< 24, oxygen saturation \> 90%, systolic blood pressure ≥ 90, return to baseline mental status based on Glasgow Coma Score, and PO diet or medication ordered

Time frame: The outcome will be assessed 90 days after enrollment

Clinical deterioration within 10 days of randomization

Defined by admission to an intensive care unit, mechanical ventilation, or in-hospital mortality on any hospital day, or supplemental oxygen \>2 L after hospital day 3

Time frame: The outcome will be assessed 10 days after enrollment

Ceftriaxone-associated toxicity within 10 days of randomization

Defined by new development of Hemoglobin \< 10, elevated liver enzymes or or total bilirubin, clinically significant diarrhea (represented by Clostridioides difficile testing), or rash (represented by consult to dermatology)

Time frame: The outcome will be assessed 10 days after enrollment

Ranked composite outcome

Rank 1 (highest rank) = no antibiotic escalation, clinical deterioration, or Ceftriaxone-associated toxicity Rank 2 = antibiotic escalation without clinical deterioration or Ceftriaxone-associated toxicity Rank 3 = Ceftriaxone-associated toxicity without clinical deterioration Rank 4 = clinical deterioration without 30-day mortality Rank 5 = 30-day mortality

Time frame: The outcome will be assessed 30 days after enrollment